Catalyst Pharma reports FY2024 revenue $491.7M (+23.5% YoY), guides FY2025 $545-565M

CATALYST PHARMACEUTICALS, INC.

2024-FY EPS reported $1.31 revenue$491,734,000

Q4 net product revenue $141.8M; full-year FIRDAPSE revenue $306M (+18.4%), AGAMREE $46M (new launch).
GAAP net income $163.9M ($1.31 diluted EPS) vs $71.4M ($0.63) in 2023; non-GAAP net income $276.3M ($2.21 diluted EPS).
Cash and equivalents $517.6M at year-end, up 276% from $137.6M a year ago.
Full year 2025 revenue guidance set at $545-565M, reflecting continued growth momentum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.